Corcept Therapeutics Incorporated (0I3Q.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 3.53B |
| Enterprise Value | 3.42B |
| P/E Ratio | 49.69 |
| PEG Ratio | 0.99 |
| Price/Sales Ratio | 8.46 |
| Price/Book Ratio | 9.53 |
| Enterprise/Revenue | 8.37 |
| Enterprise/EBITDA | 60.02 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | September 30, 2026 |
Profitability
| Profit Margin | 0.17 |
| Operating Margin | 0.12 |
AD
Management Effectiveness
| Return On Assets | 0.16 |
| Return On Equity | 0.23 |
Income Statement
| Revenue | 761.41M |
| Revenue/Share | 9.04 |
| Gross Profit | 748.43M |
| EBITDA | 46.69M |
| Net Income | 99.65M |
| Diluted EPS | 0.82 |
Balance Sheet
| Total Cash | 370.7M |
| Total Cash/Share | 3.48 |
| Total Debt | 8.99M |
| Total Debt/Equity | 0.01 |
| Current Ratio | 3 |
| Book Value Per Share | 7.82 |
Price History
| 52-Week Change | -5.97 |
| 52-Week High | 126.57 |
| 52-Week Low | 28.67 |
| Moving Average 50 Days | 106.19 |
| Moving Average 200 Days | 76.09 |
Statistics
| Average Volume | 737 |
| Shares Outstanding | 109.44M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
